Prenetics, the Hong Kong-headquartered health sciences company, reported that its IM8 nutraceutical brand generated approximately $16.7 million in revenue during May 2026 alone — a single-month record that implies roughly $200 million in annualized recurring revenue. The figure caps a record first quarter for the brand and marks one of the more notable revenue trajectories in the premium supplement segment over the past two years.
IM8 is positioned as a comprehensive daily longevity stack, bundling standardized extracts, vitamins, and bioavailability-enhanced nutrient complexes into a subscription-oriented finished formulation. The brand's structure-function claims center on cellular health, metabolic support, and healthy aging — categories that continue to attract both consumer spending and clinical investigation. While Prenetics has not published peer-reviewed trial data linked directly to the IM8 finished formulation in this announcement, the company has emphasized ingredient-level clinical evidence and third-party testing as core pillars of its quality narrative.
The broader longevity and healthy-aging supplement category has become one of the fastest-growing segments within functional nutrition. Consumer interest in NAD+ precursors, adaptogens, and mitochondrial support ingredients has driven substantial category expansion, with direct-to-consumer brands capturing an outsized share of that growth through subscription models that generate predictable, recurring revenue. IM8's annualized run rate, if sustained, would place it among a small cohort of DTC supplement brands operating above the $150 million threshold — a tier that typically attracts co-manufacturing partnerships, white-label interest, and acquisition attention from larger nutraceutical or pharmaceutical holding companies.
For operators and formulators tracking the space, IM8's trajectory reinforces several concurrent trends: consumer willingness to pay premium price points for curated multi-ingredient stacks, the compounding value of subscription retention in DTC supplement businesses, and the growing importance of brand trust and ingredient transparency as differentiators in a crowded finished-formulation market. Prenetics has leveraged its existing genomics and diagnostics infrastructure — built through its CircleDNA business — to position IM8 within a broader personalized health ecosystem, a go-to-market angle that resonates with health-engaged consumers seeking integrated wellness solutions.
The company is expected to provide additional Q2 2026 guidance as the fiscal year progresses. Industry observers will be watching whether IM8 can maintain monthly revenue momentum at this level, and whether Prenetics moves to expand the brand's retail footprint beyond its current DTC-dominant distribution model into specialty health retail or foodservice-adjacent channels.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.